New Study from StrategyR Highlights a $13 Billion Global Market for Self-Compacting Concrete by 2026 – QNT Press Release4 years ago
Abbisko Therapeutics Completed Dosing of First Patient for Its First-in-Class Highly Selective FGFR2/3 Inhibitor ABSK061 – QNT Press Release4 years ago
New Study from StrategyR Highlights a $1.3 Billion Global Market for Workflow Automation and Optimization Software by 2026 – QNT Press Release4 years ago
